



OPEN ACCESS

EDITED BY

Udayan Apte,
University of Kansas Medical Center
Research Institute, United States

REVIEWED BY

Sayee Anakk,
University of Illinois at Urbana-Champaign,
United States
Xin Tong,
University of Michigan, United States

*CORRESPONDENCE

Sarah H. Radi
✉ sarah.radi@ucr.edu

RECEIVED 20 May 2023

ACCEPTED 18 July 2023

PUBLISHED 03 August 2023

CITATION

Radi SH, Vemuri K, Martinez-Lomeli J and
Sladek FM (2023) HNF4 α isoforms: the
fraternal twin master regulators of liver
function.
Front. Endocrinol. 14:1226173.
doi: 10.3389/fendo.2023.1226173

COPYRIGHT

© 2023 Radi, Vemuri, Martinez-Lomeli and
Sladek. This is an open-access article
distributed under the terms of the [Creative
Commons Attribution License \(CC BY\)](#). The
use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

HNF4 α isoforms: the fraternal twin master regulators of liver function

Sarah H. Radi^{1*}, Kiranmayi Vemuri^{2,3}, Jose Martinez-Lomeli⁴
and Frances M. Sladek⁴

¹Department of Biochemistry, University of California, Riverside, Riverside, CA, United States,

²Department of Genetics, Human Genetics Institute of New Jersey, Rutgers, The State University of New Jersey, Piscataway, NJ, United States, ³Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States, ⁴Department of Molecular, Cell and Systems Biology, University of California, Riverside, Riverside, CA, United States

In the more than 30 years since the purification and cloning of Hepatocyte Nuclear Factor 4 (HNF4 α), considerable insight into its role in liver function has been gleaned from its target genes and mouse experiments. HNF4 α plays a key role in lipid and glucose metabolism and intersects with not just diabetes and circadian rhythms but also with liver cancer, although much remains to be elucidated about those interactions. Similarly, while we are beginning to elucidate the role of the isoforms expressed from its two promoters, we know little about the alternatively spliced variants in other portions of the protein and their impact on the 1000-plus HNF4 α target genes. This review will address how HNF4 α came to be called the master regulator of liver-specific gene expression with a focus on its role in basic metabolism, the contributions of the various isoforms and the intriguing intersection with the circadian clock.

KEYWORDS

HNF4 α , structure, isoforms, metabolism, liver

1 Introduction

Whether referred to as “the seat of the soul” as the ancient Babylonians believed, “the seat of our darkest emotions” as Plato postulated, a term of endearment in Urdu, or the literal translation of “courage” in the Zulu language, one thing is clear – almost every culture past and present recognizes the importance and uniqueness of the liver. This review will address key aspects of the transcription factor HNF4 α which is considered to be the master regulator of liver-specific gene expression, including the role of its two promoters and the alternatively spliced isoforms they regulate. Furthermore, while mutations in the human *HNF4A* gene and/or its target genes have been associated with several diseases, including hemophilia (1), inflammatory bowel disease (IBD) (2) and various cancers, including hepatocellular, colorectal, renal, and gastric carcinomas (3–5), this review will focus on its role in carbohydrate and lipid metabolism in the liver.

In 1996, *HNF4A* was identified as the gene mutated in Maturity Onset Diabetes of the Young 1 (MODY1), an inherited form of type 2 diabetes that causes diabetes in patients in young adulthood (6). Patients are born with hyperinsulinemia and increased body size, but it is not until they are older that their pancreas fails to secrete insulin in response to elevated blood glucose (7). These clinical findings highlighted the role of HNF4 α in glucose metabolism (and insulin secretion) but many questions remain about the MODY1 mutations and the precise role of the different HNF4 α isoforms in basic metabolism (8–11).

2 Liver structure and metabolic functions

The liver is the largest internal and main metabolic organ in the body. It is critical for nearly all bodily functions as it provides energy during periods of fasting/starvation, maintains homeostasis between meals and stores excess lipids and carbohydrates postprandially. Post-prandial nutrients and other chemical compounds, including glucose, lipids, amino acids and xenobiotics, make their way from the intestine directly to the liver through the hepatic portal system. The liver absorbs, packages, detoxifies, metabolizes and distributes these compounds to all the other tissues via the circulatory system.

The liver is composed of several lobes consisting primarily of hepatocytes, sinusoidal endothelial cells, stellate cells and Kupffer cells. Hepatocytes, which carry out the metabolic functions of the liver, are the predominant cell type in the liver (~70% by cell number) – this relative homogeneity, as well as the sheer size and accessibility of the liver, made it the ideal organ for early studies on tissue-specific gene expression (12).

Due to large metabolic demands of the body and the essential functions of the liver, the tissue is extremely well vascularized and uses 25% of the cardiac output although it makes up only about 2.5% of the total body weight (13, 14). Nonetheless, oxygen is not maintained at a constant pressure throughout the tissue; it differs

based on the proximity to the portal triad, which includes the portal vein, hepatic artery, and bile duct. While it is assumed that all hepatocytes are capable of the same functions, the liver is able to compartmentalize and focus certain functions via this oxygen gradient. Each lobe of the liver consists of three zones with zone one receiving the most oxygen and having the highest respiratory enzyme activity, including beta-oxidation and gluconeogenesis. Closest to the central vein, zone three is the least oxygenated and carries out glycolysis, lipogenesis, and ketogenesis (15) (Figure 1). It has been proposed that all zones play a role in liver homeostasis and regeneration (16, 17). Finally, the liver, which synthesizes bile from bilirubin, bile salts, and cholesterol to aid in fat digestion, surrounds the gallbladder, the site of bile storage.

The liver maintains glucose homeostasis between meals via release of stored glycogen and gluconeogenesis. The liver can initiate *de novo* glucose synthesis from lactate, pyruvate, oxaloacetate and/or glucogenic amino acids. Once produced, new glucose is transported through the blood to supply the brain, the muscles, and other organs with energy.

Gluconeogenesis is an energetically expensive process that is heavily regulated by hormones, such as insulin and glucagon, as well as by enzymes whose expression is regulated by various transcription factors. Gluconeogenesis in the liver is also dependent on the availability of oxaloacetate. If gluconeogenesis continues for an extended period of time, oxaloacetate levels will be depleted, and gluconeogenesis and the tricarboxylic acid (TCA) cycle will shut down. This causes the liver to switch to metabolism of fat to supply the body with energy. During starvation as well as prolonged fasting, fatty acids are broken down to produce acetyl-CoA.

During ketogenesis the liver converts acetyl-CoA into ketone bodies such as β -hydroxybutyrate, which are secreted into the bloodstream where they are transported to other organs as an energy source. This process of hepatocyte-driven ketogenesis is absolutely critical for the brain to continue to function during periods of fasting/starvation: not only can the brain not carry out gluconeogenesis, it also cannot utilize fat as an energy source.




FIGURE 1

Zonation in the liver lobule and associated metabolic pathways. The role of the different HNF4 α isoforms in the different zones remains to be determined.

Indeed, during hypoglycemia, up to two-thirds of the energy needs of the brain can be provided by ketone bodies produced in the liver. Similar to gluconeogenesis, ketogenesis is also tightly controlled by insulin, glucagon, and various transcription factors.

In addition to the gluconeogenic and ketogenic pathways, the liver is the main site for fatty acid synthesis and distribution. The liver also carries out *de novo* fatty acid synthesis from excess short chain fatty acids, carbohydrates and/or proteins. The liver can store the synthesized fat in lipid droplets, the excess of which causes non-alcoholic fatty liver disease (NAFLD). Obesity and type 2 diabetes are the most common risk factors that lead to NAFLD, which is increasing in incidence in the United States and worldwide (18). It is estimated that one-third of adults worldwide have fatty liver, and it is not always associated with obesity or alcohol (19, 20). Non-alcoholic steatohepatitis can also lead to cirrhosis and liver cancer and ultimately liver failure.

A depiction of the intersection of these metabolic pathways is shown in Figure 2. We now know that HNF4 α is critical to all of these metabolic processes. Loss of HNF4 α expression is associated with liver cirrhosis and reintroduction of HNF4 α can reverse cirrhosis (21), underscoring the essential nature of this transcription factor to overall liver function.

3 Hepatocyte nuclear factors

The hepatocyte nuclear factors (HNFs) constitute a group of transcription factors which control gene expression and development in various tissues. While they were originally identified in the liver (22–24), it was quickly found that they exhibit differential gene expression patterns across several tissues of the gastrointestinal system (25). HNF1 (POU HOMEO), HNF3

(FOXO), HNF4 and HNF6 (WINGED HELIX), belong to different transcription factor families. HNF4, the topic of this review and by far the most abundant HNF in the liver, is a member of the nuclear receptor superfamily (24) and regulator of *HNF1A* (26). In mammals, HNF4 is encoded by two distinct genes – *HNF4A* and *HNF4G*, located on human chromosomes 20 and 8, respectively (27). Another variant, HNF4 β is expressed in *Xenopus laevis*, where it shares binding sites with HNF4 α but is a less potent transactivator (28). HNF4 γ has two splice variants – HNF4 γ 1 is expressed in the kidney, intestine, colon and pancreas whereas HNF4 γ 2 is an intestine-restricted isoform (29).

4 HNF4 α forms combinatorial heterodimers among itself and with HNF4 γ

Despite extensive investigation into potential dimerization between HNF4 α and other nuclear receptors, particularly the promiscuous retinoid X receptor RXR, no credible evidence of heterodimer formation with other nuclear receptors has been reported. Furthermore, amino acid residues in HNF4 α have been identified that would prevent such heterodimerization (30–32). The exception is HNF4 γ which contains the same critical residues as HNF4 α and has been shown to heterodimerize with it (33). HNF4 α also forms transcriptionally active heterodimers among its twelve isoforms generated by alternative promoter usage and splicing. There are examples of both the homo- and heterodimers of HNF4 α regulating their own subset of target genes with varying levels of transcriptional efficiency. Individual isoforms co-expressed in cells revealed pairings such as HNF4 α 3+ α 8 and HNF4 α 2+ α 3,




FIGURE 2

Basic metabolic pathways in the liver and the transport to peripheral tissues. Hepatic HNF4 α is known to regulate genes involved in all of these processes. FAS, Fatty acid synthesis; VLDL, very low-density lipoprotein. Blue boxes indicate glucose metabolism intermediates, thought to be regulated by the P1 isoforms; while yellow and green are the lipid metabolism intermediates, thought to be regulated by the P2 isoforms.

which exhibit substantial differences in their transcriptional activity relative to the corresponding homodimers. HNF4 α 3+ α 8 activates expression of two of its targets, *CYP7A1* and *ALDOB*, at much higher levels than HNF4 α 3 or HNF4 α 8 alone. Similarly, HNF4 α 2+ α 3 acts as a “loss of function” heterodimer which downregulates the same target gene subset relative to HNF4 α 2 or HNF4 α 3 homodimers (34). These findings highlight the need for a more comprehensive study of the transcriptional profile of the various HNF4 α isoforms as functions previously ascribed to HNF4 α homodimers could potentially also be attributed to heterodimers of HNF4 α / γ or the HNF4 α isoforms.

5 HNF4 α is required for early development of the liver and pancreas

HNF4 α is first detected in the visceral endoderm at embryonic day E4.5 in the mouse. Homozygous deletion of HNF4 α in the germline is lethal at E4.5, due to defects in the visceral endoderm which prevent gastrulation (35, 36). Complementation of HNF4 α -deficient embryos with a tetraploid, embryo-derived, wild-type visceral endoderm rescues this early developmental lethality and the embryos gestate normally, underscoring the importance of HNF4 α for early development (37). Subsequently, HNF4 α is found in the liver bud from E8.5 onwards, showing early commitment towards the hepatoblast lineage and a role in the epithelial transformation of the developing liver (38, 39). Ablation of HNF4 α in murine fetal livers blocks hepatocyte differentiation and proper formation of hepatic epithelium and sinusoidal endothelium (37, 40). Accessory transcription factors HNF1 β , GATA-6, OC-1 and FOXA2 all coordinate with HNF4 α to modulate the varying stages of liver development (41).

During the course of pancreatic development, HNF4 α expression is detected in most epithelial cells of the pancreatic bud from E9.5 while in the adult it is more restricted to islet cells (42). By the onset of maturity, HNF4 α is expressed primarily in the liver, kidney and intestines although it still plays a role in the pancreas, as evidenced by mutations in the *HNF4A* gene in MODY1 patients (6). It should be noted that there are differences in the HNF4 α isoforms expressed during development of the two organs, with P1-derived HNF4 α 1-6 predominant in the liver, and P2-derived HNF4 α 7-12 predominant in the early pancreas (34, 43, 44).

6 Molecular structure of HNF4 α

As a member of the nuclear receptor superfamily of ligand-dependent transcription factors (NR2A1), HNF4 α is comprised of five distinct structural domains. The ~200 amino acid ligand binding domain (LBD) that defines the nuclear receptors contains a hydrophobic pocket that binds ligands and facilitates the transactivation of genes. Ligand binding induces conformational changes in the LBD which allows it to interact with a signature LXXLL motif in transcriptional co-activators (45) or a LXXXIXXX (I/L) motif in transcriptional co-repressors (46). However, despite being a nuclear receptor, HNF4 α is constitutively active and does

not require the binding of a ligand to mediate gene activation (47). The LBD of HNF4 α crystallizes as a canonical homodimer with intermolecular salt bridges and hydrogen bonds contributing to the stability of the interface (30, 31, 48–50).

The LBD is connected to a highly conserved DNA binding domain (DBD) by a hinge region which facilitates free rotation between the two domains and contains the nuclear localization signal (NLS) (51). The DBD, comprised of two cysteine-rich zinc finger motifs, dimerizes on the DNA even in the absence of the LBD (48, 52, 53). DNA binding induces a conformational change in the LBD of HNF4 α , revealing another dimerization interface and leading to an increase in the overall stability of the HNF4-DNA complex, a process essential for mediating its transcriptional activity (52, 53). The DBD and the LBD are bordered by two transactivation domains – AF-1 and AF-2, respectively. The 24 amino acids in the AF-1 act as a constitutive, autonomous transactivator domain, with Tyr6, Tyr14, Phe19, Lys10, and Lys17 essential for AF-1 activity (54, 55). The AF-2 domain in the C-terminal end of the LBD interacts with co-activators or other transcription factors (56). Unlike AF-1, the activity of the AF-2 domain depends on ligand binding in the LBD in most nuclear receptors, although evidently not HNF4 α (47). Somewhat unique to HNF4 is the presence of a large domain (F) at the C-terminus which represses transactivation; it contains a proline-rich region that plays a role in distinguishing between transcriptional co-activators and co-repressors in a ligand-independent fashion (57, 58). Additionally, a 10-amino acid insertion in the F domain introduced by alternative splicing modulates the repressive activity of the F domain (56). *HNF4A* is extensively modified post-translationally, including through phosphorylation and acetylation (59). These modifications are discussed in other review articles in this Special Topics edition.

More than 100 mutations in *HNF4A* have been associated with MODY1. The vast majority are in either the DBD or LBD with just a couple in the N-terminal region and none in the F domain (10). The first MODY1 mutation identified was Q268X in the middle of the LBD (6, 60). Since this mutation truncates the protein before the salt bridge that prevents heterodimerization with other nuclear receptors, there was a possibility of a dominant negative effect of this MODY1 mutation that could have impacted many other nuclear receptor pathways. Fortunately, the mutant HNF4 α protein was localized to the nuclear membrane and thus inaccessible to other transcription factors (61). There are several other nonsense mutations in MODY1 patients although the majority of the MODY1 mutations are missense mutations (10) raising the possibility of more subtle alterations in specific HNF4 α functions.

7 HNF4 α : master regulator of liver-specific gene expression

Since its initial identification, HNF4 α has been implicated in the regulation of hepatic lipid metabolism. Indeed, a liver-specific response element in the human apolipoprotein CIII (*APOC3*) gene was used to clone the first HNF4 cDNA from rat liver (24) while

APOA1 and *APOB* (which encode protein components of HDL and LDL, respectively) were early HNF4 α target genes (62, 63). Similarly, key genes involved in glucose metabolism, such as *PEPCK* (*PCK1*) and L-pyruvate kinase (*PKLR*), were also early targets of HNF4 α (64, 65), even before *MODY1* was associated with the *HNF4A* gene (6).

Using classical promoter-bashing approaches, the number of HNF4 α binding sites in target gene promoters grew quickly. By the time the first draft of the human genome was released in 2001, there were more than 70 verified HNF4 α binding sites in the literature. Early computational and wet bench approaches doubled the number of HNF4 α binding motifs (66) while the advent of Chromatin Immunoprecipitation (ChIP) followed by genomic sequencing techniques (ChIP-chip, ChIPseq assays) identified hundreds more potential HNF4 α target genes in liver and pancreas (67, 68). Since a ChIP signal is not necessarily due to direct binding to the genomic DNA and since identification of the exact sequence to which a transcription factor binds in a ChIP peak can be challenging, protein binding microarrays (PBMs) were used to accelerate the identification of HNF4 α binding sites *in vitro*. Cross referencing of those sites with expression profiling of HepG2 cells with or without HNF4 α led to the identification of 240 new direct HNF4 α human target genes, including new functional categories of genes not typically associated with HNF4 α , such as cell cycle, immune function, apoptosis, stress response, and cancer-related genes (69). It also earned HNF4 α the title of master regulator of liver-specific gene expression, which has persisted to this day (70).

The PBM technology led to the identification of more than 20,000 different DNA sequences to which HNF4 α binds as well as a binding motif unique to HNF4 α (71, 72). This is important given that many of the “orphan” nuclear receptors like HNF4, COUP-TF and RXR share a common DNA binding motif consisting of a direct repeat of AGGTCA half sites (AGGTCAxAGGTCA). Indeed, competition for control of expression of liver-specific genes by HNF4 α and other nuclear receptors was noted early on (73). The PBM studies also led to the identification of >60 unique, low affinity HNF4 α binding sites located in more than a million Alu sequences which are unique to primate genomes; this raised the possibility of sequestration of HNF4 α protein by binding repetitive genomic sequence as a novel mechanism by which to regulate HNF4 α function (74). Fortunately, HNF4 α is one of the most abundant transcription factors in the liver; the initial purification of HNF4 α required only a 5000 to 10,000-fold enrichment (24). On the RNA level, HNF4 α expression far surpasses that of all the other liver-enriched transcription factors (HNF1, C/EBP, HNF3, HNF6), all other nuclear receptors, and even TATA binding protein and RNA polymerase (75). As it turns out, the moniker of “master regulator of liver-specific gene expression” does indeed seem to be appropriate.

8 P1- vs. P2-HNF4 α

Expression of the *HNF4A* gene is driven by two highly conserved promoters, denoted P1, which is closest to the gene body, and P2, which is ~50 kb upstream. Together they drive the

expression of twelve different HNF4 α transcript variants referred to as isoforms. P1 activation leads to expression of HNF4 α 1, HNF4 α 2, HNF4 α 3, HNF4 α 4, HNF4 α 5 and HNF4 α 6; while P2 activation leads to HNF4 α 7, HNF4 α 8, HNF4 α 9, HNF4 α 10, HNF4 α 11 and HNF4 α 12 (Figure 3A). The tissue distribution of the twelve isoforms has been characterized by PCR and can be divided into well-established HNF4 α -expressing tissues and other tissues that have not been examined in detail for HNF4 α expression or function (Figure 3B) (34). The first exon of the P2 promoter (exon 1D), like the rest of the *HNF4A* gene, is highly conserved across most vertebrates (Figure 3C).

Early studies investigating HNF4 α did not explore the role of different isoforms and the majority of the studies in the adult liver focused solely on the role of the predominant P1-HNF4 α , particularly HNF4 α 1, the first transcript cloned (24). Even though the P2-isoform was discovered in 1998 in an undifferentiated pluripotent embryonal carcinoma cell line (E9) (76), it took several years before any functional differences were observed in the P1 and P2 isoforms (77). More recently, the scientific community has taken an interest in exploring the differences between the HNF4 α isoforms in all of the tissues where they are endogenously expressed (34). The small differences in protein size can sometimes be revealed using Western blot analysis, and antibodies specific to P1- and P2-HNF4 α are commercially available (3, 78).

The most well characterized and most abundantly expressed isoforms are HNF4 α 1/2 and HNF4 α 7/8, which differ in the N-terminal AF-1 domain that interacts with co-activators (56, 58, 77, 79). The P1-HNF4 α isoforms contain exon 1A while the P2 isoforms contain exon 1D. The difference between HNF4 α 1 and HNF4 α 2 (and HNF4 α 7 and HNF4 α 8) is that the latter has the ten amino acid insert in the F-domain which modulates the transcriptional activity of HNF4 α (58). The remaining domains – DBD, LBD, and hinge region – are identical in all isoforms. (Since the isoforms are very similar, though not identical, we chose the comparison to fraternal twins in the title.)

Among the 54 non-diseased human tissues in the Genotype-Tissue Expression (GTEx) Project, bulk RNAseq data shows that HNF4 α is selectively expressed in a few different tissues in the adult, with the greatest expression in liver followed by large (colon) and small intestines and then kidney and finally pancreas and stomach (Figure 4C). Both P1- and P2-driven HNF4 α isoforms are expressed in the fetal liver, although after birth the expression of P2-HNF4 α decreases dramatically and the expression of P1-HNF4 α increases (80) (Figure 4B). Initially, it was thought that P2-HNF4 α was not expressed in the normal adult liver due to repression of the P2-promoter by P1-HNF4 α (80). However, we and others have observed P2-HNF4 α expression in the adult liver at different times of the day as well as in response to fasting, high fat diet and alcoholic fatty liver (75, 81–83). Furthermore, P2-HNF4 α expression often increases in liver cancer as P1-HNF4 α expression decreases (3, 84). These and other findings lead to the dogma that P1-HNF4 α acts as a tumor suppressor in the liver while P2-HNF4 α is at least permissive of proliferation, both of which were found to be the case in colon cancer (78, 85).




FIGURE 3

HNF4 α isoforms and conservation of Exon 1D. (A) Schematic showing the gene structure of human HNF4A and its 12 transcripts, generated by alternative P1 and P2 promoters and alternative splicing in the N- and C-termini. (B) Relative mRNA expression of human HNF4 α isoforms, data from 34. (C) UCSG Genome Browser view (Multiz Alignment and Conservation track enabled) of Exon 1D adjacent to the P2 promoter of mouse *Hnf4a* gene (mm10) showing conservation from dolphin to human with only a single amino acid differing in most species (Ala13). Even non-mammalian animals such as chicken exhibits considerable conservation in Exon 1D. RNAseq reads from α 7HMZ male mice confirm the location of Exon 1D (Figure 4 and 75).

P1-HNF4 α is the predominant form expressed in the proximal tubules of the kidneys, though its precise role in that tissue remains to be determined (Figure 4B); some have speculated that it could play a role in gluconeogenesis in that tissue (86, 87). P2-HNF4 α is

the predominant form in the pancreas where it plays a role in insulin secretion from β -cells (42, 44, 88). P2-HNF4 α is also the predominant form in the stomach, though P1-HNF4 α seems to be found there as well; both isoforms apparently play a role in




FIGURE 4
HNF4α exon swap mice and expression of P1- and P2-HNF4α isoforms in different tissues. **(A)** *Hnf4a* locus in wildtype (WT) and exon swap mice ($\alpha7$ HMZ and $\alpha1$ HMZ); HNF4A protein structure with isoform-specific antibodies noted (α P1, α P2, α P1/P2). DBD, DNA binding domain; LBD, ligand binding domain. **(B)** Depiction of the HNF4α isoforms expressed in different tissues in WT, $\alpha1$ HMZ and $\alpha7$ HMZ mice. Stripes indicate both isoforms are present. **(C)** Bulk tissue expression in adult humans (males and females) for HNF4A from The Genotype-Tissue Expression (GTEx) Project. Aside, from liver, intestines and pancreas discussed in the text, expression of HNF4α in the various cell types of these different tissues has not been exhaustively examined.

differentiation of the epithelial cells as well as the development of gastric cancer (89). Both P1- and P2-driven HNF4α are expressed throughout the small intestines and the colon although anecdotal evidence suggests a relative increase in expression of P2-HNF4α as the intestinal tract progresses from the duodenum to the colon. In the distal colon, P1-HNF4α is expressed at the top of the colonic

crypts in the differentiated portion, while P2-HNF4α is expressed in the bottom half of the crypts in the proliferative compartment (78). Expression of HNF4α in the intestines and colon is relevant given that *HNF4A* is an IBD susceptibility gene (2) and P1-HNF4α (but not P2-HNF4α) is a target of Src tyrosine kinase in human colon cancer (90, 91).

9 *Hnf4a* exon swap mice

Since the whole-body HNF4 α knockout is embryonic lethal and a liver-specific knockout results in death at six weeks of age due to dyslipidemia, high serum bile acid levels and ureagenesis defects (35, 92, 93), an HNF4 α exon swap mouse model was developed to examine the effects of the HNF4 α isoforms *in vivo* (94) (Figure 4A). The model allows examination of a single group of HNF4 α isoforms, either P1- or P2-HNF4 α , using physiological levels of expression since the promoter regions are not altered. In α 7HMZ mice, exon 1A adjacent to the P1 promoter is replaced by exon 1D which is normally adjacent to the P2 promoter, creating mice that express only HNF4 α protein with the N-terminal domain of P2-HNF4 α (e.g., HNF4 α 7, HNF4 α 8, etc.) in all HNF4 α -expressing tissues. In contrast, the reciprocal swap of exon 1D for exon 1A generates mice that express only P1-HNF4 α proteins in α 1HMZ mice. Both the α 1HMZ and α 7HMZ mice are fertile and viable, unless they are subjected to various conditions of stress. The α 7HMZ mice have significantly lower levels of cholesterol, triglycerides, and free-fatty acids compared to wildtype and α 1HMZ mice, but significantly higher levels of ketone bodies. They also have fatter livers under conditions of fasting which could be due to decreased expression of apolipoproteins that export fat from the liver to the other tissues (94) (Figure 5A). This initial characterization of the exon swap mice was the first indication that the different HNF4 α isoforms may play different roles in basic metabolism. Subsequent studies by our group confirmed that livers from α 7HMZ male mice exhibit a metabolic transcriptome, rather than one specific to liver cancer (75).


In addition to HNF4 α , there are other transcription factors in the liver, especially nuclear receptors, that regulate genes involved in basic metabolism. These include: the glucocorticoid receptor (NR3C1, GR) which stimulates gluconeogenesis via interaction with HNF4 α on the *PCK1* promoter and regulates the HNF4 α promoter (65, 96, 97); the peroxisome proliferator activated receptors (NR1C, PPARs) which play critical roles in beta-oxidation of fatty acids and ketogenesis and, like HNF4 α , have fatty acids as their ligands (97, 98); and the farnesoid X receptor (FXR, NR1H4) which regulates

bile acid production and co-occupies many genes with HNF4 α in the liver (99). The nature of these interactions on the molecular level and the specificity, if any, with respect to the HNF4 α isoforms requires further investigation.

10 Mechanisms of HNF4A promoter switching

While the P1 and P2 promoters that drive the expression of the HNF4 α isoforms have been dissected for relevant regulatory elements (80, 100), a mechanism for a potential switch between the promoters in the liver is less well defined. Emerging data suggest that antisense transcripts and DNA methylation may be involved. Antisense transcripts are a class of long, single-stranded non-coding RNAs which have been shown to be widespread in mammalian genomes and act as regulatory switches in gene expression circuits (101). In humans, HNF4 α -AS1 (NR_109949.1) is a 648 nucleotide, antisense RNA located between the P1 and P2 promoters which makes it ideal for playing a role in the regulation of promoter switching; tellingly, it has also been implicated as a biomarker in hepatocellular carcinoma (HCC) and Crohn's disease (102, 103). ChIP-seq data in mouse liver reveals P1-HNF4 α binding in the vicinity of the HNF4 α -AS1 promoter while luciferase assays show that P1- but not P2-HNF4 α activates the HNF4 α -AS1 promoter (104). Moreover, HNF4 α -AS1 is primarily transcribed in the liver, kidney, and intestine where P1-HNF4 α expression is predominant and P2-HNF4 α expression is low (104) (Figures 3B and 4B).

A recent study suggests that another noncoding RNA (H19) and DNA methylation may also be involved in the re-expression of P2-HNF4 α in the adult liver (Da 83). H19 is one of several long ncRNA that regulate insulin signaling and glucose/lipid metabolism in various tissues (105). Da Li et al. found that fasting upregulates the H19 ncRNA in the liver, which subsequently increases HNF4 α , PGC1 α , PEPCK, and G6PC mRNA, and, unexpectedly, TET3 mRNA. TET3 is a DNA demethylase which increases expression of *Pck1*, *G6pc*, and glucose production. Increases in H19 and TET3 mRNA have been observed in human livers of type-2 diabetes



patients, suggesting that this mechanism is likely conserved between humans and mice (Da 83)

Importantly, conditions that increased *Tet3* expression led to a specific increase in P2-HNF4 α but not P1-HNF4 α expression. Mice injected with P2-HNF4 α specific shRNA adenoviral vector decreased fasting glucose, fasting insulin, *Pck1* and *G6pc* levels, and pyruvate tolerance (pyruvate tolerance tests are specific to gluconeogenic glucose production). Since TET3 is known to demethylate DNA and activate transcription, the authors speculate that it was demethylation of the P2-promoter that resulted in increased expression of P2-HNF4 α and showed TET3 binding to the P2 promoter in association with FOXA2. In short, P2-HNF4 α is increased in the livers of fasted mice, and leads to hepatic gluconeogenesis via activation of gluconeogenic genes such as *Pck1* and *G6pc* in conjunction with co-activator PGC1 α (Da 83). While PGC1 α was shown some time ago to be required for HNF4 α activation of *Pck1* and *G6pc* in the fasted liver, a specific HNF4 α isoform was not identified at that time (106, 107). This new study shows that PGC1 α co-activates P2-HNF4 α more effectively than P1-HNF4 α on these gluconeogenic genes (Da 83).

11 Role of HNF4 α in circadian rhythms and fasting

Daily fluctuations in physiological and behavioral processes rely on an intrinsic molecular clock and response to environmental changes (108). The intrinsic clock, or circadian rhythm, in mammals allows tissues to perform their designated function at specific times of the day and to anticipate changes from outside sources, thereby synchronizing mammalian physiology to the 24-hour solar day. Each tissue has its own peripheral clock, but they are all synchronized by the central molecular clock in the suprachiasmatic nucleus (SCN) in the brain. External cues that affect circadian behaviors are called “zeitgebers”. While the light/dark cycle is the most commonly studied zeitgeber, other zeitgebers include melatonin release and uptake, body temperature fluctuations, the feeding/fasting cycle and jet lag. Chronic jet lag induces spontaneous HCC in wild-type mice via a mechanism observed in obese humans involving nuclear receptor-controlled cholesterol and bile acid metabolism as well as xenobiotic metabolism pathways (109). Given the extensive role of HNF4 α in basic metabolism in the liver, as well as liver cancer (3, 4), it is not surprising that HNF4 α has been found to interact with proteins that regulate the circadian clock and play an active role in the hepatic circadian clock (84, 110, 111).

HNF4 α represses the transcriptional activity of the essential circadian regulator CLOCK : BMAL1 (110). ChIP-seq analysis reveals co-occupancy of HNF4 α and CLOCK : BMAL1 at many metabolic genes involved in lipid, glucose, and amino acid metabolism, creating a feedback loop in the liver-specific peripheral clock and impacting the circadian regulation of metabolic pathways. In short, HNF4 α is essential for the circadian rhythmicity of liver (and colonic cells) where it is normally expressed and alters the intrinsic clock when it is ectopically expressed. Interestingly, HNF4 α appears to inhibit the

CLOCK : BMAL1 complex by a mechanism independent of CRY1, the canonical clock repressor. All of the HNF4A isoforms examined (HNF4 α 1, HNF4 α 2 and HNF4 α 8) caused this inhibition and the DBD, LBD and F domain were all required, suggesting that a common protein structure among the isoforms is responsible for the repression (110). In a follow up study, the authors show that HNF4A and BMAL1 reciprocally regulate each other's genome-wide binding and that circadian rhythms are disturbed in *Hnf4a* knockout liver cells. The epigenetic state and accessibility of the liver genome dynamically changes throughout the day, synchronized with chromatin occupancy of HNF4A and clustered expression of circadian outputs (111).

The role of HNF4 α in circadian regulation in liver cancer has also been examined. P2-HNF4 α , which is often upregulated in liver cancer, is selectively induced in HCC, where it directly inhibits the expression of BMAL1 and leads to the cytoplasmic expression of the P1 isoform (84). Interestingly, induced expression of BMAL1 in HNF4 α -positive liver cancer cells impairs growth in culture and *in vivo*. Manipulation of the circadian clock in HNF4 α -positive HCC could be a strategy to slow or reverse growth of human HCC.

Finally, a study from our group in this issue of *Frontiers in Endocrinology* examines the effect of the P1- and P2-HNF4 α isoforms on liver gene expression using the *Hnf4a* exon swap mice (75). We found that mice expressing only P2-HNF4 α (α 7HMZ) have elevated levels of ketone bodies upon fasting but do not survive a prolonged fast as well as mice expressing only P1-HNF4 α (α 1HMZ) or wildtype (WT) mice. Endogenous P2-HNF4 α was expressed in the adult liver at ZT9 when levels of glucose are normally low and ketone body levels are high, an effect that was enhanced in CLOCK knockout mice. This is interesting when compared to P1- HNF4 α , which does not oscillate as dramatically as the P2 isoform throughout the day, remaining at relatively stable levels in both wildtype and CLOCK knockout mice (75). PBMs revealed that P2-HNF4 α and P1-HNF4 α have essentially identical DNA binding specificity even in the context of liver nuclear extracts; P1-HNF4 α also seems to have a preference for GC-rich motifs that bind SP1, consistent with interactions noted previously between these two transcription factors (95, 112). ChIPseq analysis also revealed very similar genome-wide binding of the P1 and P2 isoforms, despite a dysregulation of hundreds of genes, although there were some notable differences in chromatin binding in the *Apoa1 - Apoc3 - ApoA4* locus that correlated with levels of RNA expression (75) (Figure 5). In contrast, protein-protein interaction studies showed differential binding of HNF4 α in wild-type livers compared to α 7HMZ livers to several proteins, including those involved in the circadian clock (NFIL3, ARNTL, CLOCK) as well as nuclear receptors and other transcription factors (75). Those protein-protein interactions, as opposed to DNA specificity or access to the chromatin, are presumed to be responsible for the dysregulation of target genes in the livers of WT and α 7HMZ livers, especially in the fasted state. Metabolomic analysis showed increased levels of lipids and ketone bodies in mice expressing only P2-HNF4 α (α 7HMZ); in contrast, levels of glucose, pyruvate and citric acid were lower in the α 7HMZ mice (75), as noted previously (94). Finally, while the P2-HNF4 α hepatic transcriptome was more similar to the fetal liver transcriptome than that of WT

adult mice, it did not strongly resemble that of liver cancer and there was no increased incidence in liver tumors even in $\alpha 7\text{HMZ}$ mice more than a year old (75). This suggests that while P2-HNF4 α might be upregulated in human liver cancer, it does not appear to be a driver of the cancer phenotype, at least in mice.

12 The search for the HNF4 ligand

Crystallographic studies from two independent groups revealed a mixture of tightly bound fatty acids in the LBD of bacterially expressed HNF4 α (49, 50). This led to the conclusion that HNF4 α was not a druggable target as its ligand binding pocket was essentially permanently occupied (113). Given that bacterial cells are known to have different fatty acid compositions than mammalian cells, in order to identify HNF4 α ligand(s) from a more physiologically relevant environment, HNF4 α was immunoprecipitated from mouse liver and bound molecules were analyzed by gas chromatography/mass spectrometry (GC/MS) (47). The essential fatty acid linoleic acid (LA, 9, 12, octadecadienoic acid, C18:2, $\Delta^{9,12}$) was the only lipid found to be bound to endogenous HNF4 α protein in mouse liver. Furthermore, when HNF4 α was isolated from the livers of mice undergoing a prolonged fast, the amount of bound LA was noticeably decreased, consistent with depletion of LA during the fast. Follow up mutagenic studies in the ligand binding pocket confirmed specific binding while kinetic studies with isotopically labeled LA proved that binding was completely reversible (47). Expression profiling studies in the presence and absence of LA revealed that ligand binding only moderately affected the transcription of HNF4 α target genes, an effect which could have been due to a decreased level of HNF4 α protein in the presence of LA (47). Other nuclear receptor ligands are known to alter receptor stability, in addition to recruiting co-activators or co-repressors (114). Notably, HNF4 α appears to have high endogenous transcriptional activity in its ligand-free state; its expression is also increased in the fasted state, due in part to the fact that insulin decreases the expression of P1-HNF4 α via SREBPs (115). The role of the different HNF4 α isoforms, if any, in terms of ligand function is not known: the LBDs of P1- and P2-HNF4 α are identical but the AF-1 in other nuclear receptors is known to interact with the LBD and impact ligand function (79). There is one curious finding related to the HNF4 α isoforms and LA metabolism – $\alpha 7\text{HMZ}$ mice have greatly reduced levels of key cytochrome P450 genes that metabolize LA into bioactive oxylipins – *Cyp2c50*, *Cyp2c54* (75, 116). The significance of this finding remains to be determined.

In the end, the role, if any, of the HNF4 α ligand in the transcriptional function of the protein remains to be elucidated. Nonetheless, one wonders whether it is simply a coincidence that LA is an essential fatty acid that every animal organism must obtain ultimately from plants and that HNF4 is just one of two nuclear receptors found in the oldest living animal organisms close to the time more than a billion years ago that animals diverged from plants and fungi (32, 117–119). Furthermore, one must consider the possibility that even if modern HNF4 α is truly not functionally responsive to LA, it is possible that at some point during evolution

LA (or some other ligand) did in fact act in a classical fashion. Perhaps as other nuclear receptors, such as the PPARs, evolved as long chain fatty acid binding transcription factors, HNF4 transitioned into a different mode of regulation. For example, more than 13 phosphosites were initially identified in HNF4 α in absence of any sort of environmental cues (52), a number that has since more than doubled in Phosphosite Plus (120). Characterized phosphosites include that of AMPK (121, 122) which is activated in the fasted state, protein kinase C (PKC) (123) which has been shown to respond to polyunsaturated fatty acids like LA [e.g., (124, 125)] and Src tyrosine kinase which selectively targets P1-HNF4 α but not P2-HNF4 α (90). This selective activity of Src could explain the loss of P1-HNF4 α and the retention of P2-HNF4 α in both liver cancer and colon cancer – Src is known to be elevated in both (126).

13 Discussion

In conclusion, many questions remain about what are the most critical functions of the P1- versus P2-driven HNF4 α isoforms and why this dual promoter system has been conserved across so many species (Figure 3C). This is particularly relevant given that the exon swap mice expressing either only P1-HNF4 α or P2-HNF4 α are viable and healthy, unless they are subjugated to certain stresses. For example, $\alpha 7\text{HMZ}$ mice, which express only P2-HNF4 α , cannot survive a prolonged fast as well as WT or even $\alpha 1\text{HMZ}$ mice (75); they are also extremely sensitive to experimentally induced colitis (78). P1- and P2-HNF4 α are both expressed in the fetal liver but in a healthy, unstressed adult liver it is primarily the P1 promoter that is active as P1-HNF4 α protein represses the P2 promoter (Figure 6). In the adult liver, HNF4 α coordinates the expression of genes responsible for basic metabolism in conjunction with the circadian clock machinery, with P2-HNF4 α being expressed only during limited times of the day/night. Certain metabolic stressors, including fasting, a high fat diet, alcoholic liver disease and liver cancer increase expression of P2-HNF4 α by mechanisms that appear to involve promoter regulation by transcription factors, long ncRNAs and/or DNA methylation. Signaling molecules such as kinases could also impact the delicate balance of P1- and P2-HNF4 α proteins.

While many mutations leading to MODY1 have been found in the P2-promoter, many fewer have been found in the P1-promoter (6, 127). This led to the assumption that MODY1 mutations were relevant primarily in the pancreas, where P2-HNF4 α expression is dominant. Knowing now that P2-HNF4 α is expressed in the adult liver under certain conditions of stress – including fasting and type 2 diabetes – raises the possibility that the effects of the MODY1 mutations in the P2 promoter could be due, at least in part, to an inability to express P2-HNF4 α in the liver under key conditions (Da 83). Indeed, recent clinical findings suggest that certain MODY1 mutations in the coding regions may have an effect in the liver and kidney as well as the pancreas (11).

Similarly, the exact role of the HNF4 α isoforms in liver cancer is not completely clear. A knockout of HNF4 α increases chemically induced liver cancer in rodents and P1-HNF4 α interacts with cyclin D1 in a negative reciprocal regulatory axis to control hepatocyte




FIGURE 6

Balance of HNF4α isoforms in different stages of liver development and disease. See text for details.

proliferation (4, 128, 129). But why is P2-HNF4α increased in liver cancer? Given that P1-HNF4α has been shown to repress the P2 promoter either directly or indirectly (80, 83, 104), could it be simply that the tumor suppressive P1-HNF4α must be decreased in order for the hepatocytes to proliferate and that once its expression is reduced, P2-HNF4α expression is coincidentally increased? It will be of interest to determine whether the negative regulatory loop between P1-HNF4α and cyclin D1 pertains to P2-HNF4α as well.

Finally, it is intriguing to speculate that differential expression of P1- and P2-HNF4α in the different zones of the liver could be involved in different metabolic functions such as ketogenesis versus gluconeogenesis. Hypoxic conditions near the central vein are associated with ketogenesis while normoxia is in the zone where gluconeogenesis occurs (Figure 1). HNF4α has been shown to associate with hypoxia inducible factor (HIF) in the kidney to turn on the expression of the erythropoietin gene (*EPO*) which stimulates red blood cell production (130): that was presumably P1-HNF4α, the only promoter known to be active in the kidney (34). In contrast, in pancreatic cells *in vitro* hypoxia activates AMPK which in turn decreases expression of HNF4α, presumably P2, by some as yet unknown mechanism (131). Clearly, many questions remain about the HNF4α isoforms in the liver, the genes they regulate, and the factors/conditions that regulate them. The next 30 years of HNF4α research will hopefully answer those and other questions that have not yet been formulated.

Author contributions

All authors were responsible for conceiving, drafting, and critically revising this work, and were accountable for the accuracy and integrity of the work. All authors contributed to the article and approved the submitted version.

Funding

Work for this review was supported by the National Institute of Health (NIH R01DK127082).

Acknowledgments

Acknowledgment should be provided to Dr. Poonamjot Deol for writing assistance, language editing, and proofreading, as well as continual intellectual support and input for this project. Figures 1, 2, 3A, and 6 were created with BioRender.com. The Genotype-Tissue Expression (GTEx) Project referenced in the text was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses described in this manuscript were obtained from: the GTEx Analysis Release V8 (dbGaP accession number phs000424.vN.pN) on 05/09/2023.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

- Reijnen MJ, Sladek FM, Bertina RM, Reitsma PH. Disruption of a binding site for hepatocyte nuclear factor 4 results in hemophilia B Leyden. *Proc Natl Acad Sci United States America* (1992) 89(14):6300–3. doi: 10.1073/pnas.89.14.6300
- UK IBD Genetics Consortium, Barrett JC, Lee JC, Lees CW, Prescott NJ, Anderson CA, et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. *Nat Genet* (2009) 41(12):1330–4. doi: 10.1038/ng.483
- Tanaka T, Jiang S, Hotta H, Takano K, Iwanari H, Sumi K, et al. Dysregulated expression of P1 and P2 promoter-driven hepatocyte nuclear factor-4alpha in the pathogenesis of human cancer. *J Pathol* (2006) 208(5):662–72. doi: 10.1002/path.1928
- Walesky C, Apte U. Role of hepatocyte nuclear factor 4 α (HNF4 α) in cell proliferation and cancer. *Gene Expression* (2015) 16(3):101–8. doi: 10.3727/105221615X14181438356292
- Lv D-D, Zhou L-Y, Tang H. Hepatocyte nuclear factor 4 α and cancer-related cell signaling pathways: a promising insight into cancer treatment. *Exp Mol Med* (2021) 53(1):8–18. doi: 10.1038/s12276-020-00551-1
- Yamagata K, Furuta H, Oda N, Kaisaki PJ, Menzel S, Cox NJ, et al. Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). *Nature* (1996) 384(6608):458–60. doi: 10.1038/384458a0
- Colclough K, Bellanne-Chantelot C, Saint-Martin C, Flanagan SE, Ellard S. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha and 4 alpha in maturity-onset diabetes of the young and hyperinsulinemic hypoglycemia. *Hum Mutat* (2013) 34(5):669–85. doi: 10.1002/humu.22279
- Stanescu DE, Hughes N, Kaplan B, Stanley CA, De León DD. Novel presentations of congenital hyperinsulinism due to mutations in the MODY genes: HNF1A and HNF4A. *J Clin Endocrinol Metab* (2012) 97(10):E2026–30. doi: 10.1210/jc.2012-1356
- Chandran S, Rajadurai VS, Hoi WH, Flanagan SE, Hussain K, Yap F. A novel HNF4A mutation causing three phenotypic forms of glucose dysregulation in a family. *Front Pediatr* (2020) 8:320. doi: 10.3389/fped.2020.00320
- Çubuk H, Yağın Çapan Ö. A review of functional characterization of single amino acid change mutations in HNF transcription factors in MODY pathogenesis. *Protein J* (2021) 40(3):348–60. doi: 10.1007/s10930-021-09991-8
- Aarthi R, Aston-Mourney K, Mikocka-Walus A, Radha V, Amutha A, Anjana RM, et al. Clinical features, complications and treatment of rarer forms of maturity-onset diabetes of the young (MODY) - A review. *J Diabetes Its Complications* (2021) 35(1):107640. doi: 10.1016/j.jdiacomp.2020.107640
- Derman E, Krauter K, Walling L, Weinberger C, Ray M, Darnell JE Jr. Transcriptional control in the production of liver-specific mRNAs. *Cell* (1981) 23(3):731–9. doi: 10.1016/0092-8674(81)90436-0
- Myers JD, Hickam JB. An estimation of the hepatic blood flow and splanchnic oxygen consumption in heart failure. *J Clin Invest* (1948) 27(5):620–7. doi: 10.1172/JCI102008
- Lauit WW, Greenway CV. Conceptual review of the hepatic vascular bed. *Hepatology* (1987) 7(5):952–63. doi: 10.1002/hep.1840070527
- Özkan A, Stolley D, Cressman ENK, McMillin M, DeMorrow S, Yankeelov TE, et al. The influence of chronic liver diseases on hepatic vasculature: A liver-on-a-chip review. *Micromachines* (2020) 11(5):487. doi: 10.3390/mi11050487
- Michalopoulos GK, Bhushan B. Liver regeneration: biological and pathological mechanisms and implications. *Nat Rev Gastroenterol Hepatol* (2021) 18:40–55. doi: 10.1038/s41575-020-0342-4
- Wei Y, Wang YG, Jia Y, Li L, Yoon J, Zhang S, et al. Liver homeostasis is maintained by midlobular zone 2 hepatocytes. *Science* (2021) 371(6532):eabl8195. doi: 10.1126/science.abb1625
- Kumar R, Priyadarshi RN, Anand U. Non-alcoholic fatty liver disease: growing burden, adverse outcomes and associations. *J Clin Trans Hepatol* (2020) 8(1):76–86. doi: 10.14218/JCTH.2019.00051
- Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. *Hepatology* (2010) 51(2):679–89. doi: 10.1002/hep.23280
- Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. *Diabetol Metab Syndrome* (2020) 12:60. doi: 10.1186/s13098-020-00570-y
- Tafaleng EN, Mukherjee A, Bell A, Morita K, Guzman-Lepe J, Haep N, et al. Hepatocyte nuclear factor 4 alpha 2 messenger RNA reprograms liver-enriched transcription factors and functional proteins in end-stage cirrhotic human hepatocytes. *Hepatology Commun* (2021) 5(11):1911–26. doi: 10.1002/hep4.1763
- Courtois G, Morgan JG, Campbell LA, Fourel G, Crabtree GR. Interaction of a liver-specific nuclear factor with the fibrinogen and alpha 1-antitrypsin promoters. *Science* (1987) 238(4827):688–92. doi: 10.1126/science.3499668
- Grayson DR, Costa RH, Xanthopoulos KG, Darnell JE. One factor recognizes the liver-specific enhancers in alpha 1-antitrypsin and transthyretin genes. *Science* (1988) 239(4841 Pt 1):786–8.
- Sladek FM, Zhong WM, Lai E, Darnell JE Jr. Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. *Genes Dev* (1990) 4(12B):2353–65. doi: 10.1101/gad.4.12b.2353
- Sladek FM, Darnell JE. Mechanisms of liver-specific gene expression. *Curr Opin Genet Dev* (1992) 2(2):256–9. doi: 10.1016/S0959-437X(05)80282-5
- Kuo CJ, Conley PB, Chen L, Sladek FM, Darnell JE, Crabtree GR. A transcriptional hierarchy involved in mammalian cell-type specification. *Nature* (1992) 355(6359):457–61. doi: 10.1038/355457a0
- Drewes T, Senkel S, Holewa B, Ryffel GU. Human hepatocyte nuclear factor 4 isoforms are encoded by distinct and differentially expressed genes. *Mol Cell Biol* (1996) 16(3):925–31. doi: 10.1128/MCB.16.3.925
- Holewa B, Zapp D, Drewes T, Senkel S, Ryffel GU. HNF4beta, a new gene of the HNF4 family with distinct activation and expression profiles in oogenesis and embryogenesis of *Xenopus laevis*. *Mol Cell Biol* (1997) 17(2):687–94. doi: 10.1128/MCB.17.2.687
- Sasaki S, Urabe M, Maeda T, Suzuki J, Irie R, Suzuki M, et al. Induction of hepatic metabolic functions by a novel variant of hepatocyte nuclear factor 4 γ . *Mol Cell Biol* (2018) 38(24):e00213–18. doi: 10.1128/MCB.00213-18
- Jiang G, Nepomuceno L, Hopkins K, Sladek FM. Exclusive homodimerization of the orphan receptor hepatocyte nuclear factor 4 defines a new subclass of nuclear receptors. *Mol Cell Biol* (1995) 15(9):5131–43. doi: 10.1128/MCB.15.9.5131
- Bogan AA, Dallas-Yang Q, Ruse MD, Maeda Y, Jiang G, Nepomuceno L, et al. Analysis of protein dimerization and ligand binding of orphan receptor HNF4alpha. *J Mol Biol* (2000) 302(4):831–51. doi: 10.1006/jmbi.2000.4099
- Beinsteiner B, Markov GV, Erb S, Chebaro Y, McEwen AG, Cianferani S, et al. A structural signature motif enlightens the origin and diversification of nuclear receptors. *PLoS Genet* (2021) 17(4):e1009492. doi: 10.1371/journal.pgen.1009492
- Daigo K, Kawamura T, Ohta Y, Ohashi R, Katayose S, Tanaka T, et al. Proteomic analysis of native hepatocyte nuclear factor-4 α (HNF4 α) isoforms, phosphorylation status, and interactive cofactors. *J Biol Chem* (2011) 286(1):674–86. doi: 10.1074/jbc.M110.154732
- Ko HL, Zhuo Z, Ren EC. HNF4 α Combinatorial isoform heterodimers activate distinct gene targets that differ from their corresponding homodimers. *Cell Rep* (2019) 26(10):2549–2557.e3. doi: 10.1016/j.celrep.2019.02.033
- Chen WS, Manova K, Weinstein DC, Duncan SA, Plump AS, Prezioso VR, et al. Disruption of the HNF-4 gene, expressed in visceral endoderm, leads to cell death in embryonic ectoderm and impaired gastrulation of mouse embryos. *Genes Dev* (1994) 8(20):2466–77. doi: 10.1101/gad.8.20.2466
- Duncan SA, Nagy A, Chan W. Murine gastrulation requires HNF-4 regulated gene expression in the visceral endoderm: tetraploid rescue of Hnf-4(-/-) embryos. *Development* (1997) 124(2):279–87. doi: 10.1242/dev.124.2.279
- Li J, Ning G, Duncan SA. Mammalian hepatocyte differentiation requires the transcription factor HNF-4alpha. *Genes Dev* (2000) 14(4):464–74. doi: 10.1101/gad.14.4.464
- Battle MA, Konopka G, Parviz F, Gaggl AL, Yang C, Sladek FM, et al. Hepatocyte nuclear factor 4alpha orchestrates expression of cell adhesion proteins during the epithelial transformation of the developing liver. *Proc Natl Acad Sci United States America* (2006) 103(22):8419–24. doi: 10.1073/pnas.0600246103
- Lau HH, Ng NHJ, Loo LSW, Jasmen JB, Teo AKK. The molecular functions of hepatocyte nuclear factors - In and beyond the liver. *J Hepatol* (2018) 68(5):1033–48. doi: 10.1016/j.jhep.2017.11.026
- Parviz F, Matullo C, Garrison WD, Savatski L, Adamson JW, Ning G, et al. Hepatocyte nuclear factor 4alpha controls the development of a hepatic epithelium and liver morphogenesis. *Nat Genet* (2003) 34(3):292–6. doi: 10.1038/ng1175
- Kyrmizi I, Hatzis P, Katrakili N, Tronche F, Gonzalez FJ, Talianidis I. Plasticity and expanding complexity of the hepatic transcription factor network during liver development. *Genes Dev* (2006) 20(16):2293–305. doi: 10.1101/gad.390906
- Nammo T, Yamagata K, Tanaka T, Kodama T, Sladek FM, Fukui K, et al. Expression of HNF-4alpha (MODY1), HNF-1beta (MODY5), and HNF-1alpha (MODY3) proteins in the developing mouse pancreas. *Gene Expression Patterns* (2008) 8(2):96–106. doi: 10.1016/j.modgep.2007.09.006
- Thomas H, Jaschkoewitz K, Bulman M, Frayingling TM, Mitchell SM, Roosen S, et al. A distant upstream promoter of the HNF-4alpha gene connects the transcription factors involved in maturity-onset diabetes of the young. *Hum Mol Genet* (2001) 10(19):2089–97. doi: 10.1093/hmg/10.19.2089
- Ihara A, Yamagata K, Nammo T, Miura A, Yuan M, Tanaka T, et al. Functional characterization of the HNF4alpha isoform (HNF4alpha8) expressed in pancreatic beta-cells. *Biochem Biophys Res Commun* (2005) 329(3):984–90. doi: 10.1016/j.bbrc.2005.02.072
- Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. *Nature* (1997) 387(6634):733–6. doi: 10.1038/42750

46. Xu HE, Stanley TB, Montana VG, Lambert MH, Shearer BG, Cobb JE, et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. *Nature* (2002) 415(6873):813–7. doi: 10.1038/415813a
47. Yuan X, Ta TC, Lin M, Evans JR, Dong Y, Bolotin E, et al. Identification of an endogenous ligand bound to a native orphan nuclear receptor. *PLoS One* (2009) 4(5):e5609. doi: 10.1371/journal.pone.0005609
48. Jiang G, Sladek FM. The DNA binding domain of hepatocyte nuclear factor 4 mediates cooperative, specific binding to DNA and heterodimerization with the retinoid X receptor alpha. *J Biol Chem* (1997) 272(2):1218–25. doi: 10.1074/jbc.272.2.1218
49. Dhe-Paganon S, Duda K, Iwamoto M, Chi Y-I, Shoelson SE. Crystal structure of the HNF4 alpha ligand binding domain in complex with endogenous fatty acid ligand. *J Biol Chem* (2002) 277(41):37973–6. doi: 10.1074/jbc.C200420200
50. Wisely GB, Miller AB, Davis RG, Thornquest A. D. C.OMMAJ.R.X.X.X, Johnson R, Spitzer T, et al. Hepatocyte nuclear factor 4 is a transcription factor that constitutively binds fatty acids. *Structure* (2002) 10(9):1225–34. doi: 10.1016/S0969-2126(02)00829-8
51. Chandra V, Huang P, Potluri N, Wu D, Kim Y, Rastinejad F. Multidomain integration in the structure of the HNF-4 α nuclear receptor complex. *Nature* (2013) 495(7441):394–8. doi: 10.1038/nature11966
52. Jiang G, Nepomuceno L, Yang Q, Sladek FM. Serine/threonine phosphorylation of orphan receptor hepatocyte nuclear factor 4. *Arch Biochem Biophys* (1997) 340(1):1–9. doi: 10.1006/abbi.1997.9914
53. Eeckhoutte J, Oxombre B, Formstecher P, Lefebvre P, Laine B. Critical role of charged residues in helix 7 of the ligand binding domain in Hepatocyte Nuclear Factor 4 α dimerisation and transcriptional activity. *Nucleic Acids Res* (2003) 31(22):6640–50. doi: 10.1093/nar/gkg850
54. Green VJ, Kokkotou E, Ladias JA. Critical structural elements and multitarget protein interactions of the transcriptional activator AF-1 of hepatocyte nuclear factor 4. *J Biol Chem* (1998) 273(45):29950–7. doi: 10.1074/jbc.273.45.29950
55. Kistanova E, Dell H, Tsantili P, Falvey E, Cladaras C, Hadzopoulou-Cladaras M. The activation function-1 of hepatocyte nuclear factor-4 is an acidic activator that mediates interactions through bulky hydrophobic residues. *Biochem J* (2001) 356(Pt 2):635–42. doi: 10.1042/bj3560635
56. Sladek FM, Ruse MD, Nepomuceno L, Huang SM, Stallcup MR. Modulation of transcriptional activation and coactivator interaction by a splicing variation in the F domain of nuclear receptor hepatocyte nuclear factor 4 α . *Mol Cell Biol* (1999) 19(10):6509–22. doi: 10.1128/MCB.19.10.6509
57. Iyemere VP, Davies NH, Brownlee GG. The activation function 2 domain of hepatic nuclear factor 4 is regulated by a short C-terminal proline-rich repressor domain. *Nucleic Acids Res* (1998) 26(9):2098–104. doi: 10.1093/nar/26.9.2098
58. Ruse MD, Privalsky ML, Sladek FM. Competitive cofactor recruitment by orphan receptor hepatocyte nuclear factor 4 α : modulation by the F domain. *Mol Cell Biol* (2002) 22(6):1626–38. doi: 10.1128/MCB.22.6.1626-1638.2002
59. Beinstreiner B, Billas IML, Moras D. Structural insights into the HNF4 biology. *Front Endocrinol (Lausanne)* (2023) 14:1197063. doi: 10.3389/fendo.2023.1197063
60. Stoffel M, Duncan SA. The maturity-onset diabetes of the young (MODY1) transcription factor HNF4 α regulates expression of genes required for glucose transport and metabolism. *Proc Natl Acad Sci United States America* (1997) 94(24):13209–14. doi: 10.1073/pnas.94.24.13209
61. Sladek FM, Dallas-Yang Q, Nepomuceno L. MODY1 mutation Q268X in hepatocyte nuclear factor 4 α allows for dimerization in solution but causes abnormal subcellular localization. *Diabetes* (1998) 47(6):985–90. doi: 10.2337/diabetes.47.6.985
62. Chan J, Nakabayashi H, Wong NC. HNF-4 increases activity of the rat Apo A1 gene. *Nucleic Acids Res* (1993) 21(5):1205–11. doi: 10.1093/nar/21.5.1205
63. Metzger S, Halaas JL, Breslow JL, Sladek FM. Orphan receptor HNF-4 and bZip protein C/EBP alpha bind to overlapping regions of the apolipoprotein B gene promoter and synergistically activate transcription. *J Biol Chem* (1993) 268(22):16831–8. doi: 10.1016/S0021-9258(19)85491-1
64. Diaz Guerra MJ, Bergot MO, Martinez A, Cuif MH, Kahn A, Raymondjean M. Functional characterization of the L-type pyruvate kinase gene glucose response complex. *Mol Cell Biol* (1993) 13(12):7725–33. doi: 10.1128/mcb.13.12.7725-7733.1993
65. Hall RK, Sladek FM, Granner DK. The orphan receptors COUP-TF and HNF-4 serve as accessory factors required for induction of phosphoenolpyruvate carboxykinase gene transcription by glucocorticoids. *Proc Natl Acad Sci United States America* (1995) 92(2):412–6. doi: 10.1073/pnas.92.2.412
66. Elliott K, Yang C, Sladek FM, Jiang T. Identifying transcription factor binding sites through Markov chain optimization. *Bioinformatics* (2002) 18 Suppl 2:S100–9. doi: 10.1093/bioinformatics/18.suppl_2.S100
67. Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, et al. Control of pancreas and liver gene expression by HNF transcription factors. *Science* (2004) 303(5662):1378–81. doi: 10.1126/science.1089769
68. Schmidt D, Wilson MD, Ballester B, Schwalie PC, Brown GD, Marshall A, et al. Five-vertebrate ChIP-seq reveals the evolutionary dynamics of transcription factor binding. *Science* (2010) 328(5981):1036–40. doi: 10.1126/science.1186176
69. Bolotin E, Liao H, Ta TC, Yang C, Hwang-Verslues W, Evans JR, et al. Integrated approach for the identification of human hepatocyte nuclear factor 4 α target genes using protein binding microarrays. *Hepatology* (2010) 51(2):642–53. doi: 10.1002/hep.23357
70. Kaestner KH. Making the liver what it is: the many targets of the transcriptional regulator HNF4 α [Review of *Making the liver what it is: the many targets of the transcriptional regulator HNF4 α*]. *Hepatology* (2010) 51(2):376–7. doi: 10.1002/hep.23487
71. Fang B, Mane-Padros D, Bolotin E, Jiang T, Sladek FM. Identification of a binding motif specific to HNF4 by comparative analysis of multiple nuclear receptors. *Nucleic Acids Res* (2012) 40(12):5343–56. doi: 10.1093/nar/gks190
72. Deans JR. *The Role of Nuclear Receptors in Tissue-Specific Gene Expression: The Impact of Genetic Variation on DNA Binding*. UC Riverside (2017). Available at: <https://escholarship.org/uc/item/2cw7q5hj>.
73. Mietus-Snyder M, Sladek FM, Ginsburg GS, Kuo CF, Ladias JA, Darnell JE, et al. Antagonism between apolipoprotein AI regulatory protein 1, Ear3/COUP-TF, and hepatocyte nuclear factor 4 modulates apolipoprotein CIII gene expression in liver and intestinal cells. *Mol Cell Biol* (1992) 12(4):1708–18. doi: 10.1128/mcb.12.4.1708-1718.1992
74. Bolotin E, Chellappa K, Hwang-Verslues W, Schnabl JM, Yang C, Sladek FM. Nuclear receptor HNF4 α binding sequences are widespread in Alu repeats. *BMC Genomics* (2011) 12:560. doi: 10.1186/1471-2164-12-560
75. Deans JR, Deol P, Titova N, Radi SH, Vuong LM, Evans JR, et al. Alternative HNF4 α isoform regulates the sex-specific diurnal balance between carbohydrate and lipid metabolism in the liver. *bioRxiv* (2023) 2021.02.28.433261. doi: 10.1101/2021.02.28.433261
76. Nakhei H, Lingott A, Lemm I, Ryffel GU. An alternative splice variant of the tissue specific transcription factor HNF4 α predominates in undifferentiated murine cell types. *Nucleic Acids Res* (1998) 26(2):497–504. doi: 10.1093/nar/26.2.497
77. Torres-Padilla ME, Sladek FM, Weiss MC. Developmentally regulated N-terminal variants of the nuclear receptor hepatocyte nuclear factor 4 α mediate multiple interactions through coactivator and corepressor-histone deacetylase complexes. *J Biol Chem* (2002) 277(47):44677–87. doi: 10.1074/jbc.M207545200
78. Chellappa K, Deol P, Evans JR, Vuong LM, Chen G, Brianc¸on N, et al. Opposing roles of nuclear receptor HNF4 α isoforms in colitis and colitis-associated colon cancer. *eLife* (2016) 5. doi: 10.7554/eLife.10903
79. Warmmark A, Treuter E, Wright APH, Gustafsson J-A. Activation functions 1 and 2 of nuclear receptors: molecular strategies for transcriptional activation. *Mol Endocrinol* (2003) 17(10):1901–9. doi: 10.1210/me.2002-0384
80. Brianc¸on N, Bailly A, Clotman F, Jacquemin P, Lemaigre FP, Weiss MC. Expression of the alpha7 isoform of hepatocyte nuclear factor (HNF) 4 is activated by HNF6/OC-2 and HNF1 and repressed by HNF4 α 1 in the liver. *J Biol Chem* (2004) 279(32):33398–408. doi: 10.1074/jbc.M405312200
81. Argemi J, Latasa MU, Atkinson SR, Blokhin IO, Massey V, Gue JP, et al. Defective HNF4 α -dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis. *Nat Commun* (2019) 10(1):3126. doi: 10.1038/s41467-019-11004-3
82. Fekry B, Ribas-Latre A, Baumgartner C, Mohamed AMT, Kolonin MG, Sladek FM, et al. HNF4 α -deficient fatty liver provides a permissive environment for sex-independent hepatocellular carcinoma. *Cancer Res* (2019) 79(22):5860–73. doi: 10.1158/0008-5472.CAN-19-1277
83. Li D, Cao T, Sun X, Jin S, Xie D, Huang X, et al. Hepatic TET3 contributes to type-2 diabetes by inducing the HNF4 α fetal isoform. *Nat Commun* (2020) 11(1):342. doi: 10.1038/s41467-019-14185-z
84. Fekry B, Ribas-Latre A, Baumgartner C, Deans JR, Kwok C, Patel P, et al. Incompatibility of the circadian protein BMAL1 and HNF4 α in hepatocellular carcinoma. *Nat Commun* (2018) 9(1):4349. doi: 10.1038/s41467-018-06648-6
85. Vuong LM, Chellappa K, Dhahbi JM, Deans JR, Fang B, Bolotin E, et al. Differential effects of hepatocyte nuclear factor 4 α isoforms on tumor growth and T-cell factor 4/AP-1 interactions in human colorectal cancer cells. *Mol Cell Biol* (2015) 35(20):3471–90. doi: 10.1128/MCB.00030-15
86. Curthoys NP, Moe OW. Proximal tubule function and response to acidosis. *Clin J Am Soc Nephrol* (2014) 9(9):1627–38. doi: 10.2215/CJN.10391012
87. Legouis D, Faivre A, Cipp PE, de Seigneux S. Renal gluconeogenesis: an underestimated role of the kidney in systemic glucose metabolism. *Nephrol Dialysis Transplant* (2020) 37(8):1417–25. doi: 10.1093/ndt/gfaa302
88. Miura A, Yamagata K, Kakei M, Hatakeyama H, Takahashi N, Fukui K, et al. Hepatocyte nuclear factor 4 α is essential for glucose-stimulated insulin secretion by pancreatic beta-cells. *J Biol Chem* (2006) 281(8):5246–57. doi: 10.1074/jbc.M507496200
89. Moore BD, Khurana SS, Huh WJ, Mills JC. Hepatocyte nuclear factor 4 α is required for cell differentiation and homeostasis in the adult mouse gastric epithelium. *Am J Physiol Gastrointestinal Liver Physiol* (2016) 311(2):G267–75. doi: 10.1152/ajpgi.00195.2016
90. Chellappa K, Jankova L, Schnabl JM, Pan S, Brelivet Y, Fung CL-S, et al. Src tyrosine kinase phosphorylation of nuclear receptor HNF4 α correlates with isoform-specific loss of HNF4 α in human colon cancer. *Proc Natl Acad Sci United States America* (2012) 109(7):2302–7. doi: 10.1073/pnas.1106799109
91. Chellappa K, Robertson GR, Sladek FM. HNF4 α : a new biomarker in colon cancer? *Biomarkers Med* (2012) 6(3):297–300. doi: 10.2217/bmm.12.23
92. Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ. Hepatocyte nuclear factor 4 α (nuclear receptor 2A1) is essential for maintenance of hepatic gene

- expression and lipid homeostasis. *Mol Cell Biol* (2001) 21(4):1393–403. doi: 10.1128/MCB.21.4.1393-1403.2001
93. Inoue Y, Hayhurst GP, Inoue J, Mori M, Gonzalez FJ. Defective ureagenesis in mice carrying a liver-specific disruption of hepatocyte nuclear factor 4alpha (HNF4alpha). HNF4alpha regulates ornithine transcarbamylase *in vivo*. *J Biol Chem* (2002) 277(28):25257–65. doi: 10.1074/jbc.M203126200
94. Briancon N, Weiss MC. *In vivo* role of the HNF4alpha AF-1 activation domain revealed by exon swapping. *EMBO J* (2006) 25(6):1253–62. doi: 10.1038/sj.emboj.7601021
95. Kardassis D, Falvey E, Tsantili P, Hadzopoulou-Cladaras M, Zannis V. Direct physical interactions between HNF-4 and Sp1 mediate synergistic transactivation of the apolipoprotein CIII promoter. *Biochemistry* (2002) 41(4):1217–28. doi: 10.1021/bi015618f
96. Bailly A, Briancon N, Weiss MC. Characterization of glucocorticoid receptor and hepatocyte nuclear factor 4alpha (HNF4alpha) binding to the hnf4alpha gene in the liver. *Biochimie* (2009) 91(9):1095–103. doi: 10.1016/j.biochi.2009.06.009
97. Peeters A, Baes M. Role of PPAR α in hepatic carbohydrate metabolism. *PPAR Res* (2010) 2010. doi: 10.1155/2010/572405
98. Lin Y, Wang Y, Li P-F. PPAR α : An emerging target of metabolic syndrome, neurodegenerative and cardiovascular diseases. *Frontiers in Endocrinology*. 13 (2022) 1074911. doi: 10.3389/fendo.2022.1074911
99. Thomas AM, Hart SN, Li G, Lu H, Fang Y, Fang J, et al. Hepatocyte nuclear factor 4 alpha and farnesoid X receptor co-regulates gene transcription in mouse livers on a genome-wide scale. *Pharm Res* (2013) 30(9):2188–98. doi: 10.1007/s11095-013-1006-7
100. Hatzis P, Kyrmizi I, Talianidis I. Mitogen-activated protein kinase-mediated disruption of enhancer-promoter communication inhibits hepatocyte nuclear factor 4alpha expression. *Mol Cell Biol* (2006) 26(19):7017–29. doi: 10.1128/MCB.00297-06
101. Yelin R, Dahary D, Sorek R, Levanon EY, Goldstein O, Shoshan A, et al. Widespread occurrence of antisense transcription in the human genome. *Nat Biotechnol* (2003) 21(4):379–86. doi: 10.1038/nbt808
102. Esposti DD, Hernandez-Vargas H, Voegele C, Fernandez-Jimenez N, Forey N, Bancel B, et al. Identification of novel long non-coding RNAs deregulated in hepatocellular carcinoma using RNA-sequencing. *Oncotarget* (2016) 7(22):31862–77. doi: 10.18632/oncotarget.7364
103. Haberman Y, BenShoshan M, Di Segni A, Dexheimer PJ, Braun T, Weiss B, et al. Long ncRNA landscape in the ileum of treatment-naive early-onset Crohn disease. *Inflammatory Bowel Dis* (2018) 24(2):346–60. doi: 10.1093/ibd/izz013
104. Guo S, Lu H. Novel mechanisms of regulation of the expression and transcriptional activity of hepatocyte nuclear factor 4 α . *J Cell Biochem* (2019) 120(1):519–32. doi: 10.1002/jcb.27407
105. Yang W, Lyu Y, Xiang R, Yang J. Long noncoding RNAs in the pathogenesis of insulin resistance. *Int J Mol Sci* (2022) 23(24):16054. doi: 10.3390/ijms232416054
106. Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. *Nature* (2001) 413(6852):131–8. doi: 10.1038/35093050
107. Rhee J, Inoue Y, Yoon JC, Puigserver P, Fan M, Gonzalez FJ, et al. Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis. *Proc Natl Acad Sci United States America* (2003) 100(7):4012–7. doi: 10.1073/pnas.0730870100
108. Dyar KA, Lutter D, Artati A, Ceglia NJ, Liu Y, Armenta D, et al. Atlas of circadian metabolism reveals system-wide coordination and communication between clocks. *Cell* (2018) 174(6):1571–1585.e11. doi: 10.1016/j.cell.2018.08.042
109. Kettner NM, Voicu H, Finegold MJ, Coarfa C, Sreekumar A, Putluri N, et al. Circadian homeostasis of liver metabolism suppresses hepatocarcinogenesis. *Cancer Cell* (2016) 30(6):909–24. doi: 10.1016/j.ccell.2016.10.007
110. Qu M, Duffy T, Hirota T, Kay SA. Nuclear receptor HNF4A transrepresses CLOCK : BMAL1 and modulates tissue-specific circadian networks. *Proc Natl Acad Sci United States America* (2018) 115(52):E12305–12. doi: 10.1073/pnas.1816411115
111. Qu M, Qu H, Jia Z, Kay SA. HNF4A defines tissue-specific circadian rhythms by beaconing BMAL1::CLOCK chromatin binding and shaping the rhythmic chromatin landscape. *Nat Commun* (2021) 12(1):6350. doi: 10.1038/s41467-021-26567-3
112. Hwang-Verslues WW, Sladek FM. Nuclear receptor hepatocyte nuclear factor 4alpha1 competes with oncoprotein c-Myc for control of the p21/WAF1 promoter. *Mol Endocrinol* (2008) 22(1):78–90. doi: 10.1210/me.2007-0298
113. Sladek F. Desperately seeking ... something. *Mol Cell* (2002) 10(2):219–21. doi: 10.1016/S1097-2765(02)00605-6
114. Alexander SP, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, et al. The concise guide to PHARMACOLOGY 2015/16: overview. *Br J Pharmacol* (2015) 172(24):5729–43. doi: 10.1111/bph.13347
115. Xie X, Liao H, Dang H, Pang W, Guan Y, Wang X, et al. Down-regulation of hepatic HNF4alpha gene expression during hyperinsulinemia via SREBPs. *Mol Endocrinol* (2009) 23(4):434–43. doi: 10.1210/me.2007-0531
116. Deol P, Fahrman J, Grapov D, Yang J, Bhonsle S, Ta TC, et al. HNF4 α mediates soybean oil induced obesity, fatty liver and diabetes: role of oxylipins. *Front Endocrinol* (2023).
117. Wang DY, Kumar S, Hedges SB. Divergence time estimates for the early history of animal phyla and the origin of plants, animals and fungi. *Proc Biol Sci/The R Soc* (1999) 266(1415):163–71. doi: 10.1098/rspb.1999.0617
118. Bridgham JT, Eick GN, Larroux C, Deshpande K, Harms MJ, Gauthier MEA, et al. Protein evolution by molecular tinkering: diversification of the nuclear receptor superfamily from a ligand-dependent ancestor. *PLoS Biol* (2010) 8(10):e1000497. doi: 10.1371/journal.pbio.1000497
119. Sladek FM. What are nuclear receptor ligands? *Mol Cell Endocrinol* (2011) 334(1-2):3–13. doi: 10.1016/j.mce.2010.06.018
120. Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E. PhosphoSitePlus 2014: mutations, PTMs and recalibrations. *Nucleic Acids Res* (2015) 43(Database issue):D512–20. doi: 10.1093/nar/gku1267
121. Leclerc I, Lenzner C, Gourdon L, Vaulont S, Kahn A, Viollet B. Hepatocyte nuclear factor-4alpha involved in type 1 maturity-onset diabetes of the young is a novel target of AMP-activated protein kinase. *Diabetes* (2001) 50(7):1515–21. doi: 10.2337/diabetes.50.7.1515
122. Hong YH, Varanasi US, Yang W, Leff T. AMP-activated protein kinase regulates HNF4alpha transcriptional activity by inhibiting dimer formation and decreasing protein stability. *J Biol Chem* (2003) 278(30):27495–501. doi: 10.1074/jbc.M304112200
123. Sun K, Montana V, Chellappa K, Breliet Y, Moras D, Maeda Y, et al. Phosphorylation of a conserved serine in the deoxyribonucleic acid binding domain of nuclear receptors alters intracellular localization. *Mol Endocrinol* (2007) 21(6):1297–311. doi: 10.1210/me.2006-0300
124. Shinomura T, Asaoka Y, Oka M, Yoshida K, Nishizuka Y. Synergistic action of diacylglycerol and unsaturated fatty acid for protein kinase C activation: its possible implications. *Proc Natl Acad Sci United States America* (1991) 88(12):5149–53. doi: 10.1073/pnas.88.12.5149
125. GavriloVA NJ, Setchenska MS, Nikolova-Karakashian M, Petkova DH. Effect of a sunflower oil-supplemented diet on protein kinase activities of rat liver plasma membranes. *Int J Biochem* (1992) 24(12):1953–8. doi: 10.1016/0020-711X(92)90291-8
126. Dehm SM, Bonham K. SRC gene expression in human cancer: the role of transcriptional activation. *Biochem Cell Biol* (2004) 82(2):263–74. doi: 10.1139/o03-077
127. Ellard S, Colclough K. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young. *Hum Mutat* (2006) 27(9):854–69. doi: 10.1002/humu.20357
128. Sladek FM. The yin and yang of proliferation and differentiation: cyclin D1 inhibits differentiation factors ChREBP and HNF4 α [Review of *The yin and yang of proliferation and differentiation: cyclin D1 inhibits differentiation factors ChREBP and HNF4 α*]. *Cell Cycle* (2012) 11(17):3156–7. doi: 10.4161/cc.21721
129. Wu H, Reizel T, Wang YJ, Lapiro JL, Kren BT, Schug J, et al. A negative reciprocal regulatory axis between cyclin D1 and HNF4 α modulates cell cycle progression and metabolism in the liver. *Proc Natl Acad Sci United States America* (2020) 117(29):17177–86. doi: 10.1073/pnas.2002898117
130. Galson DL, Tsuchiya T, Tendler DS, Huang LE, Ren Y, Ogura T, et al. The orphan receptor hepatic nuclear factor 4 functions as a transcriptional activator for tissue-specific and hypoxia-specific erythropoietin gene expression and is antagonized by EAR3/COUP-TF1. *Mol Cell Biol* (1995) 15(4):2135–44. doi: 10.1128/MCB.15.4.2135
131. Sato Y, Tsuyama T, Sato C, Karim MF, Yoshizawa T, Inoue M, et al. Hypoxia reduces HNF4 α /MODY1 protein expression in pancreatic β -cells by activating AMP-activated protein kinase. *J Biol Chem* (2017) 292(21):8716–28. doi: 10.1074/jbc.M116.767574